<DOC>
	<DOC>NCT00289978</DOC>
	<brief_summary>This study assessed the efficacy, safety, and tolerability of 2 doses of oral fingolimod (1.25 mg/day and 0.5 mg/day) compared to placebo in patients with relapsing-remitting multiple sclerosis (RRMS)</brief_summary>
	<brief_title>Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Male and female patients between ages 1855 with a diagnosis of multiple sclerosis Patients with a relapsingremitting disease course Patients with EDSS score of 05.5 Patients with other chronic disease of the immune system, malignancies, acute pulmonary disease, cardiac failure, etc. Pregnant or nursing women Other protocoldefined inclusion/exclusion criteria applied to this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>FTY720</keyword>
	<keyword>Fingolimod</keyword>
</DOC>